Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
Date:9/29/2009

SAN DIEGO, Sept. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Tuesday, October 6, 2009 at 2:00pm Eastern Time (11:00am Pacific Time) during the JMP Securities Healthcare Focus Conference at the Palace Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP, CFO
                Cadence Pharmaceuticals, Inc.
                858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
2. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
3. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
7. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
8. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
10. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... ... the largest manufacturer of oats in China, is now aiming at global business expansion, ... globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly recommends ... sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are the ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting ... family, friends, and community. “Coming Home 2017” will be held on Friday ...
(Date:1/21/2017)... Santa Rosa, CA (PRWEB) , ... January 21, ... ... announce the opening of its new medical office in Petaluma, located at 167 ... full-service casting room, access to SRO sports medicine and rehabilitation services ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel Biocare™ dental implant ... media for its creos™ line of bone regenerative products. Specifically, the ... he utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 James ... & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European ... touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... New Therapeutic Option to Address Motor Symptoms and ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... Fabrizio Stocchi , European Neurological Review,2016;11(Suppl. 2): 2-15, ...
Breaking Medicine Technology: